Situation analysis study on nanomedicines regulation and assessment practices in Zazibona active countries

Simple item page
dc.contributor.advisorDube, Admire
dc.contributor.authorMudyiwenyama, Linda Gracious
dc.date.accessioned2022-03-24T07:32:55Z
dc.date.accessioned2024-10-29T14:20:10Z
dc.date.available2022-03-24T07:32:55Z
dc.date.available2024-10-29T14:20:10Z
dc.date.issued2021
dc.description>Magister Scientiae - MScen_US
dc.description.abstractNanomedicines are loosely defined as medicines that seek to apply nanotechnology. Currently, nanomedicines are available for clinical use, including treatments for cancer, high cholesterol, hepatitis, COVID-19 vaccination, among other uses (Patra et al., 2018; Gao et al., 2021). Most of the nanomedicines meet the definition of medicines according to various national legislations. Consequently, these products are regulated as medicines. Nanomedicines present major differences in biological details and increased complexity of clinical use. They integrate different technology subsets from therapeutics to imaging and integrated non-invasive diagnosis (Gaspar, 2007). These complexities require extra regulatory effort.en_US
dc.identifier.urihttps://hdl.handle.net/10566/16360
dc.language.isoenen_US
dc.publisherUniversity of Western Capeen_US
dc.rights.holderUniversity of Western Capeen_US
dc.subjectNanomedicinesen_US
dc.subjectMedicines legislationen_US
dc.subjectMedicines assessment practicesen_US
dc.subjectMedicines registrationen_US
dc.subjectZazibonaen_US
dc.titleSituation analysis study on nanomedicines regulation and assessment practices in Zazibona active countriesen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
mudyiwenyama_m_nsc_2021.pdf
Size:
1.62 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Magister Scientiae - MSc (Pharmacy Administration and Policy Regulation)